Global Neuropathic Pain Market Research Report Forecast to 2023

$4,450$6,250

Clear

Description

Global Neuropathic Pain Market Research Report, by Type (Peripheral Neuropathy, Entrapment Neuropathy, and Others), by Indication (Diabetic Neuropathy, Spinal Stenosis), by Diagnosis (Imaging, Blood Tests), by Treatment (Medication, Multimodal Therapy), by Distribution Channel (Online Pharmacies, Retail Pharmacies & Drug Stores), by End-user (Hospitals, Clinics, Research Organizations), and Region – Forecast to 2023
Market analysis

Neuropathic pain is generally caused by the peripheral nerve disorder. The higher demand for better treatment methods for pain is hopefully expected to augment the growth of the global neuropathic pain market during the forecast period 2018- 2023. Also, factors such as the introduction of the pain management centers along with higher demand for generic drugs for eliminating the higher levels of pain is anticipated to boost the growth of the global neuropathic pain market. The global neuropathic pain market is expected to exhibit a growth rate of 6.06% CAGR during the forecast period 2018- 2023.

Market segmentation

Based on its type, the global neuropathic pain market is bifurcated into entrapment neuropathy, peripheral neuropathy, post traumatic neuropathy, post herpetic neuralgia (PHN), phantom limb pain, and trigeminal neuralgia. On the basis of its indication, the market is divided into diabetic neuropathy, chemotherapy-induced peripheral neuropathy, and spinal stenosis. Based on its diagnosis, the market is segmented into blood tests, imaging, and physical examination. On the basis of its treatment, the market is classified into medication type and multimodal therapy. Major end-users include clinics, hospitals, and research organizations. Lastly, on the basis of its distribution channels, the market is divided into online pharmacies and retail pharmacies & drug stores.

Regional analysis

Geographically, the global neuropathic pain market is divided into global regions like Europe, North America, Asia- Pacific, Middle East, LATAM, and Africa.

Major players

Sanofi S.A. (France), Abbott Laboratories (U.S.), AstraZeneca (U.K.), GlaxoSmithKline plc (U.K.), and Depomed Inc. (U.S.), Eli Lilly and Company (U.S.), Astellas Pharma Inc. (Tokyo), Biogen Inc. (U.S.), Baxter Healthcare Corporation (U.S.), Pfizer, Inc. (U.S.), among others are some of the major players in the global neuropathic pain market.

Table of Contents

Table of Contents:

1 Executive Summary
2 Market Introduction
2.1 Scope of Study
2.2 Research Objective
2.3 List of Assumptions
2.4 Market Structure
3 Research Methodology
3.1 Research Process
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
3.5 Forecast Model
4 Market Dynamics
4.1 Introduction
4.2 Drivers
4.2.1 Rising prevalence of diabetic neuropathy within the region
4.2.2 Increasing healthcare expenditure
4.3 Restraints
4.3.1 Increasing counterfeit drugs & side effects of therapeutic treatments
4.3.2 Lack of awareness about the neurological condition
4.4 Opportunities
4.4.1 Growing government funding for healthcare
5 Market Factor Analysis
5.1 Porter’s Five Forces Model
5.1.1 Bargaining Power of Suppliers
5.1.2 Bargaining Power of Buyers
5.1.3 Threat of New Entrants
5.1.4 Threat of Substitutes
5.1.5 Intense Rivalry
5.2 Value chain analysis
5.2.1 R&D
5.2.2 Manufacturing
5.2.3 Distribution & Sales
5.2.4 Post-Sales Monitoring
6 Global Neuropathic Pain Market, By Type
6.1 Overview
6.1.1 Peripheral Neuropathy
6.1.2 Entrapment Neuropathy
6.1.3 Phantom Limb Pain
6.1.4 Trigeminal Neuralgia
6.1.5 Post Herpetic Neuralgia (PHN)
6.1.6 Post Traumatic Neuropathy
7 Global Neuropathic Pain Market, By Indication
7.1 Overview
7.2 Diabetic Neuropathy
7.3 Chemotherapy Induced Peripheral Neuropathy
7.4 Spinal Stenosis
8 Global Neuropathic Pain Market, By Diagnosis
8.1 Overview
8.2 Imaging
8.3 Physical Examination
8.4 Blood Tests
9 Global Neuropathic Pain Market, By Treatment
9.1 Overview
9.2 Medication
9.2.1 Medication Type
9.2.1.1 NSAIDs Type
9.2.1.2 Nerve Blocks Type
9.2.1.3 Antidepressant Drugs Type
9.3 Multimodal Therapy
10 Global Neuropathic Pain Market, By Distribution Channel
10.1 Overview
10.2 Retail Pharmacies & Drug Stores
10.3 Online Pharmacies
11 Global Neuropathic Pain Market, By End-User
11.1 Overview
11.2 Hospitals
11.3 Clinics
11.4 Research Organizations
12 Global Neuropathic Pain Market, By Region
12.1 Introduction
12.2 Americas
12.2.1 North America
12.2.2 US
12.2.3 Canada
12.2.4 South America
12.3 Europe
12.3.1 Western Europe
12.3.2 Germany
12.3.3 UK
12.3.4 France
12.3.5 Spain
12.3.6 Italy
12.3.7 Rest of Western Europe
12.3.8 Eastern Europe
12.4 Asia Pacific
12.4.1 China
12.4.2 Japan
12.4.3 India
12.4.4 Australia
12.4.5 Rest of Asia Pacific
12.5 Middle East & Africa
12.5.1 The Middle East
12.5.1.1 United Arab Emirates
12.5.1.2 Saudi Arabia
12.5.1.3 Oman
12.5.1.4 Kuwait
12.5.1.5 Qatar
12.5.1.6 Egypt
12.5.1.7 Jordan
12.5.1.8 Iran
12.5.1.9 Iraq
12.5.1.10 Lebanon
12.5.2 Africa
12.5.2.1 South Africa
12.5.2.2 Morocco
12.5.2.3 Tunisia
12.5.2.4 Algeria
12.5.3 Rest of Middle East & Africa
13 Company Landscape
13.1 Company Market Share Analysis
13.1.1 Introduction
13.2 Competitive Landscape
13.2.1 Introduction
13.3 Key Developments
14 Company Profile
14.1 Sanofi
14.1.1 Company Overview
14.1.2 Financial Overview
14.1.3 Products Offering
14.1.4 Key Developments
14.1.5 SWOT Analysis
14.1.6 Key Strategy
14.2 Pfizer Inc.
14.2.1 Company Overview
14.2.2 Financial Overview
14.2.3 Products Offering
14.2.4 Key Developments
14.2.5 SWOT Analysis
14.2.6 Key Strategy
14.3 Abbott Laboratories
14.3.1 Company Overview
14.3.2 Financial Overview
14.3.3 Products Offering
14.3.4 Key Developments
14.3.5 SWOT Analysis
14.3.6 Key Strategy
14.4 GlaxoSmithKline Plc (GSK)
14.4.1 Company Overview
14.4.2 Financial Overview
14.4.3 Products Offering
14.4.4 Key Developments
14.4.5 SWOT Analysis
14.4.6 Key Strategy
14.5 Eli Lilly and Company
14.5.1 Company Overview
14.5.2 Financial Overview
14.5.3 Products Offering
14.5.4 Key Developments
14.5.5 SWOT Analysis
14.5.6 Key Strategy
14.6 Johnson & Johnson Services Inc.
14.6.1 Company Overview
14.6.2 Financial Overview
14.6.3 Products Offering
14.6.4 Key Developments
14.6.5 SWOT Analysis
14.6.6 Key Strategy
14.7 Depomed Inc.
14.7.1 Company Overview
14.7.2 Financial Overview
14.7.3 Products Offering
14.7.4 Key Developments
14.7.5 SWOT Analysis
14.7.6 Key Strategy
14.8 AstraZeneca
14.8.1 Company Overview
14.8.2 Financial Overview
14.8.3 Products Offering
14.8.4 Key Developments
14.8.5 SWOT Analysis
14.8.6 Key Strategy
14.9 Astellas Pharma Inc.
14.9.1 Company Overview
14.9.2 Financial Overview
14.9.3 Products Offering
14.9.4 Key Developments
14.9.5 SWOT Analysis
14.9.6 Key Strategy
14.1 Biogen Inc.
14.10.1 Company Overview
14.10.2 Financial Overview
14.10.3 Products Offering
14.10.4 Key Developments
14.10.5 SWOT Analysis
14.10.6 Key Strategy
14.11 Baxter Healthcare Corporation
14.11.1 Company Overview
14.11.2 Financial Overview
14.11.3 Products Offering
14.11.4 Key Developments
14.11.5 SWOT Analysis
14.11.6 Key Strategy
15 Appendix
15.1 Discussion Blue Print

Additional information

Publisher

Geography Covered

Date Published

Pages

Format